Sam Brusco, Associate Editor08.28.23
Israeli manufacturer BioProtect has gained U.S. Food and Drug Administration (FDA) clearance for its BioProtect Balloon Implant system.
The biodegradable balloon is a new-generation spacer for optimal, consistent, and reproducible rectum protection during prostate cancer radiation surgery.
"We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy," Itay Barnea, CEO of BioProtect told the press. "Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy."
"The BioProtect Balloon offers me the opportunity to optimize treatment for almost all men with prostate cancer, even those with high-risk disease. The fact that it provides additional space with a pre-formed contour, the ability to adjust its position, and high visibility with all imaging modalities would make it the choice for my patients," says Edward Soffen, MD, of Princeton Radiation Oncology.
BioProtect also appointed Ken Knudson as general manager and chief commercial officer. Knudson will lead activity in the U.S. He have a track record in urology and medical devices, including previous roles at CR Bard, Augmenix, and Boston Scientific.
The biodegradable balloon is a new-generation spacer for optimal, consistent, and reproducible rectum protection during prostate cancer radiation surgery.
"We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy," Itay Barnea, CEO of BioProtect told the press. "Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy."
"The BioProtect Balloon offers me the opportunity to optimize treatment for almost all men with prostate cancer, even those with high-risk disease. The fact that it provides additional space with a pre-formed contour, the ability to adjust its position, and high visibility with all imaging modalities would make it the choice for my patients," says Edward Soffen, MD, of Princeton Radiation Oncology.
BioProtect also appointed Ken Knudson as general manager and chief commercial officer. Knudson will lead activity in the U.S. He have a track record in urology and medical devices, including previous roles at CR Bard, Augmenix, and Boston Scientific.